ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.175,21
1,01%
S&P 500
5.180,74
1,03%
Dow Jones
38.852,27
0,46%
Euro vs US Dollar
1,07654
-0,02%
Bitcoin
63.519,20
0,56%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) News

MRTX Mirati Therapeutics Inc

58,70
0,00 (0,00%)
06 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Mirati Therapeutics Inc MRTX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,00 0,00% 58,70 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
58,70 58,70
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
14.2.202420:51EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202415:13EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02.2.202422:05EDGAR2Form 15-12G - Securities registration termination [Section..
25.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
24.1.202402:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.1.202402:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23.1.202415:31EDGAR2Form S-8 POS - Securities to be offered to employees in..
23.1.202415:30EDGAR2Form POSASR - Post-effective Amendment to an automatic shelf..
23.1.202415:28EDGAR2Form POS AM - Post-Effective amendments for registration..
23.1.202415:27EDGAR2Form POS AM - Post-Effective amendments for registration..
23.1.202414:48EDGAR2Form 8-K - Current report
18.1.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.1.202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.1.202414:00PRNUSEuropean Commission Approves KRAZATI (adagrasib) as a..
09.1.202423:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202423:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202400:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202423:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.1.202423:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202322:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19.12.202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.12.202313:30EDGAR2Form 8-K - Current report
14.12.202323:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.12.202322:30EDGAR2Form 8-K - Current report
06.12.202314:29EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
01.12.202322:43EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
24.11.202322:45EDGAR2Form 8-K - Current report
15.11.202314:49EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10.11.202313:30PRNUSMirati Therapeutics Receives Positive Opinion from CHMP for..
06.11.202314:05EDGAR2Form 8-K - Current report
06.11.202314:00PRNUSMirati Therapeutics Reports Third Quarter 2023 Financial..
06.11.202313:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.11.202322:19PRNUSMirati Therapeutics Receives Approval from the MHRA for..
02.11.202312:30EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
02.11.202312:30GLOBEKura Oncology and Mirati Therapeutics Enter into Clinical..
23.10.202323:31EDGAR2Form PREM14A - Preliminary proxy statements relating to..
17.10.202322:00PRNUSMirati Presents Late-Breaking Results Evaluating the..
11.10.202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10.10.202313:35EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
10.10.202313:33EDGAR2Form 8-K - Current report
10.10.202313:31EDGAR2Form DEFA14A - Additional definitive proxy soliciting..

Kürzlich von Ihnen besucht

NASDAQ
MRTX
Mirati Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten